BAC
Bank of America Corporation
BAC has the edge over EGBN overall, supported by stronger valuation and stronger modeled upside.
EGBN
Eagle Bancorp, Inc.
EGBN's outlook is improving despite an expensive valuation.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
EGBN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
EGBN's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like EGBN.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over EGBN in the historical PE scenario, which offers more potential upside but is not a forecast.
EGBN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.8x | $9.58 | -72% |
| Fair | 9.3x | $13.05 | -62% |
| Expensive | 11x | $15.45 | -55% |
| Forward | 15x | $34.38 | — |
| Current | 24x | $34.38 | — |
Historical ranges are pointers, not guarantees.
EGBN's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over EGBN on the outlook, with more favorable revenue expectations.
EGBN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect EGBN's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over EGBN on earnings, with more consistent year-over-year improvement.
EGBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.28 | +62% |
| Q3 2026 | $1.41 | +$5.36 |
| Q2 2026 | -$1.60 | -$0.59 |
| Q1 2026 | -$4.13 | -$2.64 |
| Q4 2025 | -$4.55 | -$2.99 |
| Q3 2025 | -$3.95 | -$2.56 |
| Q2 2025 | -$1.01 | +$0.19 |
| Q1 2025 | -$1.49 | -159% |
| Q4 2024 | -$1.56 | -147% |
EGBN has returned to profit: it earned $1.41 per share over the past year, after losing money the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over EGBN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over EGBN on profitability, with a higher operating margin.
EGBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $70.9M | +0.3% |
| Q2 2026 | $73.1M | -1.5% |
| Q1 2026 | $76.4M | +3.4% |
| Q4 2025 | $80.5M | +7.5% |
| Q3 2025 | $70.7M | -10% |
| Q2 2025 | $74.2M | -3.3% |
| Q1 2025 | $73.9M | -5.7% |
| Q4 2024 | $74.9M | -1.4% |
EGBN's revenue fell from its 2020 peak and has held roughly level since: $71M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +149 points |
| Q2 2026 | 10% | +158 points |
| Q1 2026 | 21% | +18 points |
| Q4 2025 | -6.2% | -33 points |
| Q3 2025 | -119% | -153 points |
| Q2 2025 | -147% | -44 points |
| Q1 2025 | 3.3% | -0.1 points |
| Q4 2024 | 26% | -6.4 points |
EGBN's operating margin was 30% last quarter, up 149 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
EGBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $54.2M | +242% |
| Q2 2026 | $31.5M | +$60.9M |
| Q1 2026 | $14.3M | -67% |
| Q3 2025 | $15.8M | -72% |
| Q2 2025 | -$29.3M | -153% |
| Q1 2025 | $43M | +1413% |
| Q3 2024 | $55.6M | +17% |
| Q2 2024 | $55.2M | +80% |
EGBN has the edge over BAC in the latest year-over-year cash flow comparison.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over EGBN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
EGBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +64K shares |
| 1 year | +0.9% | +266K shares |
| 3 years | +2.3% | +690K shares |
| 5 years | -4.4% | -1.4M shares |
| Available history | -10% | -3.6M shares |
EGBN has 31M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | $2,000 |
| Q3 2023 | $2,000 |
| Q2 2023 | $29.7M |
| Q1 2023 | $18.4M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
EGBN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.5x | Healthy |
| Q1 2024 | 16.2x | High |
| Q4 2023 | 0.7x | Very low |
| Q3 2023 | 0.4x | Very low |
| Q2 2023 | 0.4x | Very low |
| Q1 2023 | 0.4x | Very low |
| Q4 2022 | 5.5x | High |
| Q3 2022 | 0.2x | Very low |
EGBN has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
EGBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.5 | Overbought |
| Stochastic | 89.0 | Overbought |
EGBN's weekly RSI is 73 (overbought) and its Stochastic is 89 (overbought).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC has the edge over EGBN on valuation relative to its sector.
EGBN PE vs Financial Services Sector
| Metric | EGBN | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 13x | 87% above |
| PE % | 100 | 63 | 37 pts above |
EGBN is trading at 24x earnings, a 87% premium to the Financial Services sector's median of 13x.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
EGBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.1 | 11% above |
| 20 week MA | $29.2 | 18% above |
| 50 week MA | $26.8 | 28% above |
| 100 week MA | $23.5 | 46% above |
| 200 week MA | $24.5 | 40% above |
EGBN has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
EGBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $48.8 | $41.0 | -16% |
| 2021 | $41.0 | $56.8 | +39% |
| 2022 | $56.8 | $44.6 | -21% |
| 2023 | $44.6 | $30.1 | -32% |
| 2024 | $30.1 | $26.0 | -14% |
| 2025 | $26.0 | $21.2 | -19% |
| 2026 YTD | $21.2 | $34.4 | +62% |
EGBN has the edge over BAC on returns for 2026, with the stronger performance.